What is REPL's current stock price?

REPL (Replimune Group, Inc.) is currently trading at $4.91 with a market cap of $405.4M.

What sector is Replimune Group, Inc. in?

Replimune Group, Inc. (REPL) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is REPL a good stock to buy?

Analysts have a Hold consensus on REPL with a price target of $14.00. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

REPL Replimune Group, Inc.

Healthcare

$4.91-5.94%ClosedMarket Cap: $405.4M

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

2.15

P/S

0.00

EV/EBITDA

-1.15

DCF Value

$0.33

FCF Yield

-69.9%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-102.7%

ROA

-94.4%

ROIC

-113.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q3 null	$0.00	$-70.9M	$—
Q2 null	$0.00	$-83.1M	$—
Q1 null	$0.00	$-86.7M	$—
Q4 null	$0.00	$-74.1M	$—

Analyst Ratings

View All

Consensus

Hold

Target (Consensus)

$14.00

Target (Median)

$14.00

Target Range

$14.00 - $14.00

0 Strong Buy0 Buy5 Hold2 Sell1 Strong Sell

HC Wainwright & Co.Sell

2026-04-13

Cantor FitzgeraldNeutral

2026-04-13

Leerink PartnersMarket Perform

2026-04-13

JP MorganUnderweight

2026-04-13

JefferiesHold

2026-04-13

Trading Activity

Insider Trades

View All

Xynos Konstantinosofficer: Chief Medical Officer

SellWed May 20

Schwendenman Andrewofficer: Chief Accounting Officer

SellWed May 20

Sarchi Christopherofficer: Chief Commercial Officer

SellWed May 20

Patel Sushildirector, officer: Chief Executive Officer

SellWed May 20

Hill Emily Luisaofficer: Chief Financial Officer

SellWed May 20

Latest News

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Replimune Group, Inc. – REPLGlobeNewsWire · Tue May 12

Replimune Receives Complete Response Letter from the FDA for RP1 Biologics License Application for the Treatment of Advanced MelanomaGlobeNewsWire · Fri Apr 10

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.12

Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.

Peers

DNA

MBX